While CMS has started making changes to address health equity through policy and payment models, commercial plans are waiting to see the outcomes before they follow suit, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
While CMS has started making changes to address health equity through policy and payment models, commercial plans are waiting to see the outcomes before they follow suit, said Jayson Slotnik, partner, Health Policy Strategies, Inc.
Transcript
CMS is tweaking value-based payment models to address equity better. Are commercial plans already doing this or will they start following in the footsteps of CMS and begin to address equity in payment models?
So, in the last couple of years, CMS has had a significant emphasis on health equity. A significant approach introduced many policies related to trying to equitize access to health care across race, gender, age, socioeconomic status. And the ramifications of such are not really well known yet, because the policies haven't really gone into effect, number one, and certainly, we have not seen any data or results or research about health outcomes related to those efforts.
So, will commercial [plans] follow? It's hard to really say whether the commercial will follow. My guess is that they will wait and see what happens with Medicare. They will wait and see what's the outcomes of some of these innovative or different programs or investments, if you will, that CMS is making into these new policies—access, dedication to ignored areas of health care. And if they see a [return on investment] or even a better outcome that will cost them a little bit more, I want to believe that the commercial will follow.
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More